Jasper Therapeutics, Inc. (JSPR): restructuring charge — Jasper Therapeutics cuts workforce ~50%, halts non-urticaria programs; CMO departs

Jasper Therapeutics, Inc.

Workforce reduction of ~50% and halting of all non-chronic urticaria programs.
Estimated $1.8M-$2.2M in severance cash expenditures through Q3 2025.
CMO Edwin Tucker departs effective Aug 1, 2025; receives 12 months base salary and COBRA.
Dr. Daniel Adelman appointed Acting Chief Medical Officer effective Aug 1, 2025.
Focus on briquilimab in CSU/CIndU; data from BEACON/SPOTLIGHT expected later this year.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Jasper Therapeutics, Inc. announced a restructuring with charges of approximately $1.8 million - $2.2 million affecting the Company (approximately 50%).

Type: restructuring
Charge: approximately $1.8 million - $2.2 million
Affected area: the Company
Headcount: approximately 50%

Exact text from the filing

in chronic urticaria and is halting other clinical and preclinical programs along with the reduction in workforce. The Company estimates that it will incur approximately $1.8 million - $2.2 million of cash expenditures in connection with the corporate reorganization, which relate to severance pay, and are expected to be incurred through the quarter ending

View on SEC.gov

Browse all restructurings & charges →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-062194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.